🏛️ Verified NIH Record • Updated 2026-08-03

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors (NCT04083599)

A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Genmab

🩺 Plain-English Summary (8th-Grade Level)

The goal of this trial is to learn about the antibody GEN1042 when it is used alone and when it is used together with another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of participants with certain types of cancer.

Who can join: Review the eligibility criteria below.

Location: Alaska Oncology and Hematology LLC — Anchorage, Alaska

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (76 Sites)

Showing the first 25 of 76 sites.

  • Alaska Oncology and Hematology LLC — Anchorage, Alaska
  • Cancer & Blood Specialty Clinic — Los Alamitos, California
  • Moores Cancer Center at the UC San Diego Health — San Diego, California
  • Yale University Cancer Center — New Haven, Connecticut
  • ChristianaCare — Newark, Delaware
  • Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida
  • Florida Cancer Affiliates — Ocala, Florida
  • Hope and Healing Cancer Services — Hinsdale, Illinois
  • University of Kentucky — Lexington, Kentucky
  • Norton Cancer Institute — Louisville, Kentucky
  • Maryland Oncology Hematology PA — Columbia, Maryland
  • Washington University School of Medicine — St Louis, Missouri
  • Levine Cancer Center — Charlotte, North Carolina
  • Novant Health Cancer Institute - Forsyth (Medical Oncology) — Winston-Salem, North Carolina
  • Kaiser Permanente (KP) Oncology/Hematology — Portland, Oregon
  • University of Pennsylvania — Philadelphia, Pennsylvania
  • Fox Chase Cancer Center — Philadelphia, Pennsylvania
  • Sarah Cannon Research Institute — Nashville, Tennessee
  • Lumi Research — Kingwood, Texas
  • Utah Cancer Specialists — Salt Lake City, Utah
  • Virgina Cancer Specialists — Fairfax, Virginia
  • Adventist Health System/Sunbelt,Inc — Seattle, Washington
  • Medical Oncology Associates, PS — Spokane, Washington
  • Rigshospitalet (Copenhagen University Hospital) — Copenhagen,
  • Herlev University Hospital — Herlev,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
  • 💵 Compensation indicated: Participants will receive either GEN1042 alone, GEN1042 with pembrolizumab, or GEN1042 with pembrolizumab and chemotherapy.

Explore by condition: All Malignant Solid Tumor clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗